Arsenic trioxide and leukemia from bedside to bench

Natural Products: Drug Discovery and Therapeutic Medicine

Volumn , Issue , 2005, Pages 251-272

  Chen, Guo Qiang ^a,b   Wang, Qiong ^c   Yan, Hua ^c   Chen, Zhu ^c  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Shanghai Jiao Tong University Affiliated Sixth People s Hospital   (China)

^c SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

Author keywords

acute promyelocytic leukemia (APL); apoptosis; Arsenic trioxide; cancer; clinical trials; differentiation; leukemia

Indexed keywords

EID: 84892256412     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-59259-976-9_11     Document Type: Chapter

References (117)

1. Huang ME, Ye YC, Chen SR, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988;72:567-572.
2. Wang ZY, Chen Z. Differentiation and apoptosis induction therapy in acute promyelocytic leukaemia. Lancet Oncol 2002;1:101-106.
3. Tallmann MS. Curative therapeutic approaches to APL. Ann Hematol 2004;83:S81-S82.
4. Wicke RW, Cheung CS. Principles for applying traditional Chinese medicine to cases of cancer. Integr Cancer Ther 2002;1:175-178.
5. Chu DT, Wong WL, Mavligit GM. Immunotherapy with Chinese medicinal herbs. I. Immune restoration of local xenogeneic graft-versus-host reaction in cancer patients by fractionated Astragalus membranaceus in vitro. J Clin Lab Immunol 1998;25:119-123.
6. Cohen I, Tagliaferri M, Tripathy D. Traditional Chinese medicine in the treatment of breast cancer. Semin Oncol 2002;29:563-574.
7. Tang W, Hemm I, Bertram B. Recent development of antitumor agents from Chinese herbal medicines. Part II. High molecular compounds. Planta Med 2003;69:193-201.
8. Wang ZY. Arsenic compounds as anticancer agents. Cancer Chemother Pharmacol 2001;48:S72-S76.
9. Huang SL, Guo EX, Xiang Y. Qing Dai tablet treats acute promyelocytic leukemia: clinical reports. Chinese J Hematology 1995;16:26-28.
10. Melnick A, Licht JD. Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 1999;93:3167-2151.
11. Freemantle SJ, Spinella MJ, Dmitrovsky E. Retinoids in cancer therapy and chemoprevention: promise meets resistance. Oncogene 2003;22:7305-7315.
12. Wang ZY, Chen Z. Differentiation and apoptosis induction therapy in acute promyelocytic leukaemia. Lancet Oncol 2000;1:101-106.
13. Chen GQ and Cai X. Clinical and experimental studies on arsenicals in treatment of hematopoietic malignancies. In: Niho Y (ed). Molecular Target for Hematological Malignancies and Cancer. Kyushu University Press, 2000; pp. 85-93.
14. Cohen MH, Hirschfeld S, Flamm Honig S, et al. Drug approval summaries: arsenic trioxide, tamoxifen citrate, anastrazole, paclitaxel, bexarotene. Oncologist 2001;6:4-11.
15. Jones D E H and Ledingham K W L Arsenic in Napoleon's wallpaper. Nature 1982;299:626-627.
16. Ng JC, Wang J, Shraim A. A global health problem caused by arsenic from natural sources. Chemosphere 2003;52:1353-1359.
17. Waxman S, Anderson KC. History of the development of arsenic derivatives in cancer therapy. Oncologist 2001;6:S2-S10.
18. Forkner CE, Scott T F M. Arsenic as a therapeutic agent in chronic myelogenous leukemia. JAMA 1931;97:3-5.
19. Kandel EV, Le Roy GV. Chronic arsenical poisoning during the treatment of chronic myeloid leukemia. Arch Intern Med 1937;60:846-866.
20. Sun HD, Ma L, Hu XC, Zhang TD. Treatment of acute promyelocytic leukemia by A1-1 therapy. Chin J Integrat Chin Trad Med Western Med 1992;12:170-117.
21. Chen GQ, Zhu J, Shi XG, et al. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (ATO) in the treatment of acute promyelocytic leukemia: ATO induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RARa/PML proteins. Blood 1996;88:1052-1061.
22. Mervis J. Ancient remedy performs new tricks. Science 1996;273:578.
23. Soignet SL, Maslak P, Wang ZG, et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 1998;339:1341-1348.
24. Soignet SL, Frankel S, Tallman M. US multicenter trial of arsenic trioxide (AT) in acute promyelocytic leukemia (APL). Blood 1999;94:698a.
25. Mathews V, Balasubramanian P, Shaji RV, George B, Chandy M, Srivastava A. Arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: a single center experience. Am J Hematol 2002;70:292-299.
26. Lazo G, Kantarjian H, Estey E, Thomas D, O'Brien S, Cortes J. Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia: the M. D. Anderson experience. Cancer 2003;97:2218-2224.
27. Shen ZX, Chen GQ, Ni JH, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997;89:3354-3360.
28. Ishitsuka K, Shirahashi A, Iwao Y, et al. Bone marrow necrosis in a patient with acute promyelocytic leukemia during re-induction therapy with arsenic trioxide. Eur J Haematol 2004;72:280-284.
29. Shen Y, Shen ZX, Yan H, et al. Studies on the clinical efficacy and pharmacokinetics of lowdose arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia: a comparison with conventional dosage. Leukemia 2001;15:735-741.
30. Chen GQ, Shen ZX, Wu F, et al. Pharmacokinetics and efficacy of low-dose all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Leukemia 1996;10:825-828.
31. Hermine O, Dombret H, Poupon J, et al. Phase II trial of arsenic trioxide and alpha interferon in patients with relapsed/refractory adult T-cell leukemia/lymphoma. Hematol J 2004;5:130-134.
32. Zhang P, Wang SY, Hu XH. Arsenic trioxide-treated 72 cases of acute promyelocytic leukemia. Chin J Hematol 1996;17:58-60.
33. Zhang P, Wang SY, Hu LH, et al. Seven years' summary report on the treatment of acute promyelocytic leukemia with arsenic trioxide: an analysis of 242 cases. Chin J Hematol 2000;21:67-70.
34. Niu C, Yan H, Yu T, et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia. Blood 1999;94:3315-3324.
35. Barbui T, Finazzi G, Falanga A. The impact of all-trans-retinoic acid on the coagulopathy of acute promyelocytic leukemia. Blood 1998;91:3093-3102.
36. Zhu J, Guo WM, Yao YY, et al. Tissue factors on acute promyelocytic leukemia and endothelial cells are differently regulated by retinoic acid, arsenic trioxide and chemotherapeutic agents. Leukemia 1999;13:1062-1070.
37. Agis H, Weltermann A, Mitterbauer G, et al. Successful treatment with arsenic trioxide of a patient with ATRA-resistant relapse of acute promyelocytic leukemia. Ann Hematol 1999;78(7):329-332.
38. Ohsawa M, Koyama T, Shibakura M, Kamei S, Hirosawa S. Arsenic trioxide (As2O3) gradually downregulates tissue factor expression without affecting thrombomodulin expression in acute promyelocytic leukemia cells. Leukemia 2000;14:941-943.
39. Camacho LH, Soignet SL, Chanel S, et al. Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide. J Clin Oncol 2000;18:2620-2625.
40. Lin CP, Huang MJ, Chang IY, Lin WY, Sheu YT. Retinoic acid syndrome induced by arsenic trioxide in treating recurrent all-trans retinoic acid resistant acute promyelocytic leukemia. Leuk Lymphoma 2000;38:195-198.
41. Ohnishi K, Yoshida H, Shigeno K, et al. Prolongation of the qt interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia. Ann Intern Med 2000;133:881-885.
42. Galm O, Fabry U, Osieka R. Pseudotumor cerebri after treatment of relapsed acute promyelocytic leukemia with arsenic trioxide. Leukemia 2000;14:343-344.
43. Hu J, Shen ZX, Sun GL, Chen SJ, Wang ZY, Chen Z. Long-term survival and prognostic study in acute promyelocytic leukemia treated with all-trans-retinoic acid, chemotherapy, and As2O3: an experience of 120 patients at a single institution. Int J Hematol 1999;70:248-260.
44. Tanvetyanon T, Nand S. Herpes zoster during treatment with arsenic trioxide. Ann Hematol 2004;83:198-200.
45. Zhang T, Westervelt P, Hess JL. Pathologic, cytogenetic and molecular assessment of acute promyelocytic leukemia patients treated with arsenic trioxide (As2O3). Mod Pathol 2000;13:954-961.
46. Raffoux E, Rousselot P, Poupon J, et al. Combined treatment with arsenic trioxide and alltrans-retinoic acid in patients with relapsed acute promyelocytic leukemia. J Clin Oncol 2003;21:2326-2334.
47. Shen ZX, Shi ZZ, Fang J, et al. All-trans retinoic acid/ATO combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA 2004;101:5328-5335.
48. Lu DP, Qiu JY, Jiang B, et al. Tetra-arsenic tetra-sulfide for the treatment of acute promyelocytic leukemia: a pilot report. Blood 2002;99:3136-3143.
49. Chen GQ, Shi XG, Tang W, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. Blood 1997;89:3345-3353.
50. Lallemand-Breitenbach V, Guillemin MC, Janin A, et al. Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia. J Exp Med 1999;189:1043-1052.
51. Kinjo K, Kizaki M, Muto A, et al. Arsenic trioxide (As2O3)-induced apoptosis and differentiation in retinoic acid-resistant acute promyelocytic leukemia model in hGM-CSF-producing transgenic SCID mice. Leukemia 2000;14:431-438.
52. Lanotte M, Martin-Thouvenin V, Najman S, Balerini P, Valensi F, Berger R. NB4, a maturation inducible cell line with t (15;17) marker isolated from a human acute promyelocytic leukemia (M3). Blood 1991;77:1080-1086.
53. Zhang TD, Chen GQ, Wang ZG, Wang ZY, Chen SJ, Chen Z. Arsenic trioxide, a therapeutic agent for APL. Oncogene 2001;20:7146-7153.
54. Wang X. The expanding role of mitochondria in apoptosis. Genes Dev 2001;15:2922-2933.
55. Zhu XH, Shen YL, Jing YK, et al. Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations. J Natl Cancer Inst 1999;91:772-778.
56. Cai X, Shen YL, Zhu Q, et al. Arsenic trioxide-induced apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukemia. Leukemia 2000;14:262-270.
57. Larochette N, Decaudin D, Jacotot E, et al. Arsenite induces apoptosis via a direct effect on the mitochondrial permeability transition pore. Exp Cell Res 1999;249:413-421.
58. Kroemer G, de The H. Arsenic trioxide, a novel mitochondriotoxic anticancer agent? J Natl Cancer Inst 1999;91:743-745.
59. Liu P, Han ZC. Treatment of acute promyelocytic leukemia and other hematologic malignancies with arsenic trioxide: review of clinical and basic studies. Int J Hematol. 2003;78:32-39.
60. Akao Y, Yamada H, Nakagawa Y. Arsenic-induced apoptosis in malignant cells in vitro. Leuk Lymphoma 2000;37:53-63.
61. Huang XJ, Wiernik PH, Klein RS, Gallagher RE. Arsenic trioxide induces apoptosis of myeloid leukemia cells by activation of caspases. Med Oncol 1999;16:58-64.
62. Kitamura K, Minami Y, Yamamoto K, et al. Involvement of CD95-independent caspase 8 activation in arsenic trioxide-induced apoptosis. Leukemia 2000;14:1743-1750.
63. Liu Q, Hilsenbeck S, Gazitt Y. Arsenic trioxide-induced apoptosis in myeloma cells: p53-dependent G1 or G2/M cell cycle arrest, activation of caspase-8 or caspase-9, and synergy with APO2/TRAIL. Blood 2003;101:4078-4087.
64. Huang C, Ma WY, Li J, Dong Z. Arsenic induces apoptosis through a c-Jun. NH2-terminal kinase-dependent, p53-independent pathway. Cancer Res 1999;59:3053-3058.
65. Jiang XH, Chun-Yu Wong B, et al. Arsenic trioxide induces apoptosis in human gastric cancer cells through up-regulation of p53 and activation of caspase-3. Int J Cancer 2001;91:173-179.
66. Rojewski MT, Korper S, Thiel E, Schrezenmeier H. Depolarization of mitochondria and activation of caspases are common features of arsenic (III)-induced apoptosis in myelogenic and lymphatic cell lines. Chem Res Toxicol 2004;17:119-128.
67. Gurr JR, Bau DT, Liu F, Lynn S, Jan KY. Dithiothreitol enhances arsenic trioxide-induced apoptosis in NB4 cells. Mol Pharmacol 1999;56:102-109.
68. Davison K, Cote S, Mader S, Miller WH. Glutathione depletion overcomes resistance to arsenic trioxide in arsenic-resistant cell lines. Leukemia 2003;17:931-940.
69. Dai J, Weinberg RS, Waxman S, Jing Y. Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood 1999;93:268-277.
70. Quignon F, Chen Z, de The H. Retinoic acid and arsenic: towards oncogene-targeted treatments of acute promyelocytic leukaemia. Biochim Biophys Acta 1997;1333:M53-M61.
71. Andre C, Guillemin MC, Zhu J, et al. The PML and PML/RARalpha domains: from autoimmunity to molecular oncology and from retinoic acid to arsenic. Exp Cell Res 1996;229:253-260.
72. Costantini P, Belzacq AS, Vieira HL, et al. Oxidation of a critical thiol residue of the adenine nucleotide translocator enforces Bcl-2-independent permeability transition pore opening and apoptosis. Oncogene 2000;19:307-314.
73. Pelicano H, Feng L, Zhou Y, et al. Inhibition of mitochondrial respiration: a novel strategy to enhance drug-induced apoptosis in human leukemia cells by a reactive oxygen species-mediated mechanism. J Biol Chem 2003;278:37, 832-37, 839.
74. Uslu R, Sanli UA, Sezgin C, et al. Arsenic trioxide-mediated cytotoxicity and apoptosis in prostate and ovarian carcinoma cell lines. Clin Cancer Res 2000;6:4957-4964.
75. Gupta S, Yel L, Kim D, Kim C, Chiplunkar S, Gollapudi S. Arsenic trioxide induces apoptosis in peripheral blood T lymphocyte subsets by inducing oxidative stress: a role of Bcl-2. Mol Cancer Ther 2003;2:711-719.
76. Grad JM, Bahlis NJ, Reis I, Oshiro MM, Dalton WS, Boise LH. Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells. Blood 2001;98:805-813.
77. Yi J, Yang J, He R, et al. Emodin enhances arsenic trioxide-induced apoptosis via generation of reactiveoxygen species and inhibition of survival signaling. Cancer Res 2004;64:108-116.
78. Liu L, Trimarchi JR, Navarro P, Blasco MA, Keefe DL. Oxidative stress contributes to arsenicinduced telomere attrition, chromosome instability, and apoptosis. J Biol Chem 2003;278:31, 998-32, 004.
79. Park IC, Park MJ, Woo SH, et al. Tetraarsenic oxide induces apoptosis in U937 leukemic cells through a reactive oxygen species-dependent pathway. Int J Oncol 2003;23:943-948.
80. Davison K, Mann KK, Waxman S, Miller WH Jr. JNK activation is a mediator of arsenic trioxide-induced apoptosis in acute promyelocytic leukemia cells. Blood 2004;103:3496-3502.
81. Chen F, Castranova V, Li Z, Karin M, Shi X. Inhibitor of nuclear factor kappaB kinase deficiency enhances oxidative stress and prolongs c-Jun. NH2-terminal kinase activation induced by arsenic. Cancer Res 2003;63:7689-7693.
82. Kajiguchi T, Yamamoto K, Hossain K, et al. Sustained activation of c-jun-terminal kinase (JNK) is closely related to arsenic trioxide-induced apoptosis in an acute myeloid leukemia (M2)-derived cell line, NKM-1. Leukemia 2003;17:2189-2195.
83. Huang MJ, Hsieh RK, Lin CP, Chang IY, Liu HJ. The cytotoxicity of arsenic trioxide to normal hematopoietic progenitors and leukemic cells is dependent on their cell-cycle status. Leuk Lymphoma 2002;43:2191-2199.
84. Huang S, Huang CF, Lee T. Induction of mitosis-mediated apoptosis by sodium arsenite in HeLa S3 cells. Biochem Pharmacol 2000;60:771-780.
85. Park JW, Choi YJ, Jang MA, et al. Arsenic trioxide induces G2/M growth arrest and apoptosis after caspase-3 activation and bcl-2 phosphorylation in promonocytic U937 cells. Biochem Biophys Res Commun 2001;286:726-734.
86. Ling YH, Jiang JD, Holland JF, Perez-Soler R. Arsenic trioxide produces polymerization of Mtubules and mitotic arrest before apoptosis in human tumor cell lines. Mol Pharmacol 2002;62:529-538.
87. Cai X, Yu Y, Huang Y, et al. Arsenic trioxide-induced mitotic arrest and apoptosis in acute promyelocytic leukemia cells. Leukemia 2003;17:1333-1337.
88. Jing Y. The PML-RARalpha fusion protein and targeted therapy for acute promyelocytic leukemia. Leuk Lymphoma 2004;45(4):639-648.
89. Sun Y, Kim SH, Zhou DC, et al. Acute promyelocytic leukemia cell line AP-1060 established as a cytokine-dependent culture from a patient clinically resistant to all-trans retinoic acid and arsenic trioxide. Leukemia 2004;18(7):1258-1269.
90. Chen Z, Chen GQ, Shen ZX, Chen SJ, Wang ZY. Treatment of acute promyelocytic leukemia with arsenic compounds: In vitro and in vivo studies. Semin Hemat 2001;38:26-36.
91. Hong SH, Yang Z, Privalsky ML. Arsenic trioxide is a potent inhibitor of the interaction of SMRT corepressor with Its transcription factor partners, including the PML-retinoic acid receptor alpha oncoprotein found in human acute promyelocytic leukemia. Mol Cell Biol 2001;21:7172-7182.
92. Jiang G, Bi K, Tang T, et al. Effect of arsenic trioxide on cytokine expression by acute promyelocytic leukemia cells. Chin Med J (Engl) 2003;116:1639-1643.
93. Chelbi-alix MK, Bobe P, Benoit G, Canova A, Pine R. Arsenic enhances the activation of Stat1 by interferon gamma leading to synergistic expression of IRF-1. Oncogene 2003;22:9121-9130.
94. Zhu Q, Zhang JW, Zhu HQ, et al. Synergic effects of arsenic trioxide and cAMP during acute promyelocytic leukemia cell maturation subtends a novel signaling cross-talk. Blood 2002;99:1014-1022.
95. Huang Y, Du KM, Xue ZH, et al. Cobalt chloride and low oxygen tension trigger differentiation of acute myeloid leukemic cells: possible mediation of hypoxia-inducible factor-1alpha. Leukemia 2003;17:2065-2073.
96. Zhu J, Koken MH, Quignon F, et al. Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia. Proc Natl Acad Sci USA 1997;94:3978-3983.
97. Muller S, Matunis MJ, Dejean A. Conjugation with the ubiquitin-related modifier SUMO-1 regulates the partitioning of PML within the nucleus. EMBO J 1998;17:61-70.
98. Sternsdorf T, Puccetti E, Jensen K, et al. PIC-1/SUMO-1-modified PML-retinoic acid receptor alpha mediates arsenic trioxide-induced apoptosis in acute promyelocytic leukemia. Mol Cell Biol 1999;19:5170-5178.
99. Muller S, Miller WH, Dejean A. Trivalent antimonials induce degradation of the PML-RAR oncoprotein and reorganization of the promyelocytic leukemia nuclear bodies in acute promyelocytic leukemia NB4 cells. Blood 1998;92:4308-4316.
100. Kitamura K, Hoshi S, Koike M, Kiyoi H, Saito H, Naoe T. Histone deacetylase inhibitor but not arsenic trioxide differentiates acute promyelocytic leukaemia cells with t (11;17) in combination with all-trans retinoic acid. Br J Haematol 2000;108:696-702.
101. Koken MH, Daniel MT, Gianni M, et al. Retinoic acid, but not arsenic trioxide, degrades the PLZF/RARalpha fusion protein, without inducing terminal differentiation or apoptosis, in a RA-therapy resistant t (11;17) (q23;q21) APL patient. Oncogene 1999;18:1113-1118.
102. Puccetti E, Beissert T, Guller S, et al. Leukemia-associated translocation products able to activate RAS modify PML and render cells sensitive to arsenic-induced apoptosis. Oncogene 2003;22:6900-6908.
103. Hayakawa F, Privalsky ML. Phosphorylation of PML by mitogen-activated protein kinases plays a key role in arsenic trioxide-mediated apoptosis. Cancer Cell 2004;5:389-401.
104. Roboz GJ, Dias S, Lam G, et al. Arsenic trioxide induces dose-and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis. Blood 2000;96:1525-1530.
105. Lew YS, Brown SL, Griffin RJ, Song CW, Kim JH. Arsenic trioxide causes selective necrosis in solid murine tumors by vascular shutdown. Cancer Res 1999;59:6033-6037.
106. Chen GQ, Zhou L, Styblo M, et al. Methylated metabolites of arsenic trioxide are more potent than arsenic trioxide as apoptotic but not differentiation inducers in leukemia and lymphoma cells. Cancer Res 2003;63:1853-1859.
107. Wang Z, Zhou J, Lu X, Gong Z, Le XC. Arsenic speciation in urine from acute promyelocytic leukemia patients undergoing arsenic trioxide treatment. Chem Res Toxicol 2004;17:95-103.
108. Ochi T, Nakajima F, Sakurai T, et al. Dimethylarsinic acid causes apoptosis in HL-60 cells via interaction with glutathione. Arch Toxicol 1996;70:815-821.
109. Hussein MA. Trials of arsenic trioxide in multiple myeloma. Cancer Control 2003;10:370-374.
110. Bazarbachi A, Hermine O. Treatment of adult T-cell leukaemia/lymphoma: current strategy and future perspectives. Virus Res 2001;78:79-92.
111. Murgo AJ. Clinical trials of arsenic trioxide in hematologic and solid tumors: overview of the National Cancer Institute Cooperative Research and Development Studies. Oncologist 2001;6:22-28.
112. Ishitsuka K, Hanada S, Suzuki S, et al. Arsenic trioxide inhibits growth of human T-cell leukaemia virus type I infected T-cell lines more effectively than retinoic acids. Br J Haematol 1998;103:721-728.
113. Bazarbachi A, El-Sabban ME, Nasr R, et al. Arsenic trioxide and interferon-alpha synergize to induce cell cycle arrest and apoptosis in human T-cell lymphotropic virus type I-transformed cells. Blood 1999;93:278-283.
114. El-Sabban ME, Nasr R, Dbaibo G, et al. Arsenic-interferon-alpha-triggered apoptosis in HTLV-I transformed cells is associated with tax down-regulation and reversal of NF-kappa B activation. Blood 2000;96:2849-2855.
115. El-Sabban ME, Nasr R, Dbaibo G, et al. Arsenic-interferon-alpha-triggered apoptosis in HTLV-I transformed cells is associated with tax down-regulation and reversal of NF-kappaB activation. Blood 2000;96:2849-2855.
116. Nasr R, Rosenwald A, El-Sabban ME, et al. Arsenic/interferon specifically reverses 2 distinct gene networks critical for the survival of HTLV-1-infected leukemic cells. Blood 2003;101:4576-4582.
117. Vuky J, Yu R, Schwartz L, Motzer RJ. Phase II trial of arsenic trioxide in patients with metastatic renal cell carcinoma. Invest New Drugs 2002;20:327-330.